Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 2
2002 2
2003 2
2004 3
2005 4
2006 1
2007 5
2008 2
2009 2
2010 2
2012 1
2013 3
2014 3
2015 3
2016 3
2017 4
2018 3
2019 1
2020 3
2021 6
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Colon cancer.
Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S, Pessi MA, Prochilo T, Quadri A, Gatta G, de Braud F, Wils J. Labianca R, et al. Among authors: mosconi s. Crit Rev Oncol Hematol. 2010 May;74(2):106-33. doi: 10.1016/j.critrevonc.2010.01.010. Crit Rev Oncol Hematol. 2010. PMID: 20138539 Review.
Cholangiocarcinoma.
Squadroni M, Tondulli L, Gatta G, Mosconi S, Beretta G, Labianca R. Squadroni M, et al. Among authors: mosconi s. Crit Rev Oncol Hematol. 2017 Aug;116:11-31. doi: 10.1016/j.critrevonc.2016.11.012. Epub 2016 Nov 25. Crit Rev Oncol Hematol. 2017. PMID: 28693792 Free article. Review.
Cholangiocarcinoma.
Mosconi S, Beretta GD, Labianca R, Zampino MG, Gatta G, Heinemann V. Mosconi S, et al. Crit Rev Oncol Hematol. 2009 Mar;69(3):259-70. doi: 10.1016/j.critrevonc.2008.09.008. Epub 2008 Nov 1. Crit Rev Oncol Hematol. 2009. PMID: 18977670 Review.
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Cremolini C, et al. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. Lancet Oncol. 2020. PMID: 32164906 Free article. Clinical Trial.
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.
Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, Rugge M, Grigioni W, Bencardino K, Lonardi S, Zagonel V, Leone F, Noe J, Ciardiello F, Pinto C, Labianca R, Mosconi S, Graiff C, Aprile G, Frau B, Garufi C, Loupakis F, Racca P, Tonini G, Lauricella C, Veronese S, Truini M, Siena S, Marsoni S, Gambacorta M. Valtorta E, et al. Among authors: mosconi s. Mod Pathol. 2015 Nov;28(11):1481-91. doi: 10.1038/modpathol.2015.98. Epub 2015 Oct 9. Mod Pathol. 2015. PMID: 26449765 Free article. Clinical Trial.
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.
Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreas J, Virdee PS, Dutton P, Love S, Gebski V, Gray A; FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-Global trial investigators; van Hazel G, Sharma RA. Wasan HS, et al. Lancet Oncol. 2017 Sep;18(9):1159-1171. doi: 10.1016/S1470-2045(17)30457-6. Epub 2017 Aug 3. Lancet Oncol. 2017. PMID: 28781171 Free PMC article. Clinical Trial.
Colorectal cancer: screening.
Labianca R, Beretta GD, Mosconi S, Milesi L, Pessi MA. Labianca R, et al. Among authors: mosconi s. Ann Oncol. 2005;16 Suppl 2:ii127-32. doi: 10.1093/annonc/mdi730. Ann Oncol. 2005. PMID: 15958442 Free article. Review. No abstract available.
Adjuvant treatment of colorectal cancer.
Beretta GD, Milesi L, Pessi MA, Mosconi S, Labianca R. Beretta GD, et al. Among authors: mosconi s. Surg Oncol. 2004 Aug-Nov;13(2-3):63-73. doi: 10.1016/j.suronc.2004.09.008. Surg Oncol. 2004. PMID: 15572088 Review.
Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA Trial.
Basile D, Rosati G, Bergamo F, Garattini SK, Banzi M, Zampino M, Bozzarelli S, Marchetti P, Galli F, Galli F, Longarini R, Zaniboni A, Ferrari D, De Placido S, Frassineti LG, Nicolini M, Cinieri S, Priscindiaro M, Ziranu P, Caccialanza R, Pastorino A, Mosconi S, Aprile G. Basile D, et al. Among authors: mosconi s. Clin Colorectal Cancer. 2023 Jun;22(2):190-198. doi: 10.1016/j.clcc.2023.01.004. Epub 2023 Feb 5. Clin Colorectal Cancer. 2023. PMID: 36935327 Clinical Trial.
The development of clinical research in CRC.
Labianca R, Beretta GD, Mosconi S, Pessi MA, Milesi L. Labianca R, et al. Among authors: mosconi s. Ann Oncol. 2005 May;16 Suppl 4:iv37-43. doi: 10.1093/annonc/mdi906. Ann Oncol. 2005. PMID: 15923427 Free article. Review. No abstract available.
53 results